355 related articles for article (PubMed ID: 15386266)
1. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
Fiorentini S; Marini E; Bozzo L; Trainini L; Saadoune L; Avolio M; Pontillo A; Bonfanti C; Sarmientos P; Caruso A
Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
[TBL] [Abstract][Full Text] [Related]
2. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
3. Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study.
Iaria ML; Fiorentini S; Focà E; Zicari S; Giagulli C; Caccuri F; Francisci D; Di Perri G; Castelli F; Baldelli F; Caruso A
Vaccine; 2014 Feb; 32(9):1072-8. PubMed ID: 24456624
[TBL] [Abstract][Full Text] [Related]
4. Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17.
Fiorentini S; Marsico S; Becker PD; Iaria ML; Bruno R; Guzmán CA; Caruso A
Vaccine; 2008 Aug; 26(36):4758-65. PubMed ID: 18602957
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.
Sarin PS; Mora CA; Naylor PH; Markham R; Schwartz D; Kahn J; Heseltine P; Gazzard B; Youle M; Rios A
Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):401-7. PubMed ID: 7580834
[TBL] [Abstract][Full Text] [Related]
7. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection.
Okuda K; Kaneko T; Yamakawa T; Tanaka S; Shigematsu T; Yamamoto A; Hamajima K; Nakajima K; Kawamoto S; Phanuphak P
J Mol Recognit; 1993 Sep; 6(3):101-9. PubMed ID: 8060667
[TBL] [Abstract][Full Text] [Related]
8. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
Martin SJ; Vyakarnam A; Cheingsong-Popov R; Callow D; Jones KL; Senior JM; Adams SE; Kingsman AJ; Matear P; Gotch FM
AIDS; 1993 Oct; 7(10):1315-23. PubMed ID: 8267904
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.
Fiorentini S; Giagulli C; Caccuri F; Magiera AK; Caruso A
Pharmacol Ther; 2010 Dec; 128(3):433-44. PubMed ID: 20816696
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor.
De Francesco MA; Baronio M; Fiorentini S; Signorini C; Bonfanti C; Poiesi C; Popovic M; Grassi M; Garrafa E; Bozzo L; Lewis GK; Licenziati S; Gallo RC; Caruso A
Proc Natl Acad Sci U S A; 2002 Jul; 99(15):9972-7. PubMed ID: 12105273
[TBL] [Abstract][Full Text] [Related]
11. Antibody recognition of synthetic peptides mimicking immunodominant regions of HIV-1 p24 and p17 proteins.
Lottersberger J; Salvetti JL; Beltramini LM; Tonarelli G
Rev Argent Microbiol; 2004; 36(4):151-7. PubMed ID: 15786866
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 matrix protein p17 modulates in vivo preactivated murine T-cell response and enhances the induction of systemic and mucosal immunity against intranasally co-administered antigens.
Fiorentini S; Becker PD; Marini E; Marconi P; Avolio M; Tosti G; Link C; Manservigi R; Guzman CA; Caruso A
Viral Immunol; 2006; 19(2):177-88. PubMed ID: 16817760
[TBL] [Abstract][Full Text] [Related]
13. Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag.
de Goede AL; Boers PH; Dekker LJ; Osterhaus AD; Gruters RA; Rimmelzwaan GF
Vaccine; 2009 Sep; 27(42):5735-9. PubMed ID: 19647812
[TBL] [Abstract][Full Text] [Related]
14. cDNA encoding a single-chain antibody to HIV p17 with cytoplasmic or nuclear retention signals inhibits HIV-1 replication.
Tewari D; Goldstein SL; Notkins AL; Zhou P
J Immunol; 1998 Sep; 161(5):2642-7. PubMed ID: 9725267
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
[TBL] [Abstract][Full Text] [Related]
16. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
[TBL] [Abstract][Full Text] [Related]
17. Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual.
Harrer T; Harrer E; Barbosa P; Kaufmann F; Wagner R; Brüggemann S; Kalden JR; Feinberg M; Johnson RP; Buchbinder S; Walker BD
J Immunol; 1998 Nov; 161(9):4875-81. PubMed ID: 9794421
[TBL] [Abstract][Full Text] [Related]
18. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2.
McGettigan JP; Koser ML; McKenna PM; Smith ME; Marvin JM; Eisenlohr LC; Dietzschold B; Schnell MJ
Virology; 2006 Jan; 344(2):363-77. PubMed ID: 16226782
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine--HGP-30-KLH.
Naylor PH; Sztein MB; Wada S; Maurer S; Holterman D; Kirkley JE; Naylor CW; Zook BC; Hitzelberg RA; Gibbs CJ
Int J Immunopharmacol; 1991; 13 Suppl 1():117-27. PubMed ID: 1823903
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
Hewer R; Meyer D
Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
